Novartis plots 2,500 more job cuts

CEO Daniel Vasella (photo) gave us the broad outline two days ago. Now here are the details: Novartis is slashing its payroll by 2,500 jobs, or 2.5 percent of its worldwide workforce. The cutbacks are designed to save $1.6 billion in annual costs by 2010; Novartis will take a $450 million charge to pay for the program. In October, the company announced it would cut 1,250 jobs, mostly in the U.S. These new cuts come on top of those, bringing the grand total to 3,750 jobs.

The litany of Novartis' woes is familiar to anyone in pharma these days. The company has new generic competition for three of its big drugs. It's been stymied in getting new drugs to market; witness Galvus, which has been delayed because of safety concerns. Another blow was the withdrawal of its bowel drug Zelnorm earlier this year.

This less-than-stellar news has depressed Novartis stock by 8.8 percent this year. But the market likes the cutback plan: Shares were up 1.6 percent this morning.

- check out the release on the layoffs
- read this BBC report
- take a look at the article from Dow Jones

Related Articles:
CEO: Novartis plans big restructuring. Report
Top 5 layoffs of 2007 (Updated). Report
Lagging sales spur Novartis layoffs. Report
Novartis makes the "Biggest Splash". Report
Novartis bankrolls a drug manufacturing revolution. Report

Suggested Articles

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Intercept presented a data analysis that found treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests.

Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.